Kintara Therapeutics Granted Extension By Nasdaq To Regain Compliance With The Stockholders' Equity Continued Listing Requirement
Portfolio Pulse from Benzinga Newsdesk
Kintara Therapeutics, Inc. (NASDAQ:KTRA) has been granted an extension by Nasdaq to regain compliance with the stockholders' equity continued listing requirement. The company must meet certain milestones by March 18, 2024, to avoid potential delisting. Failure to comply by the end of the quarter on March 31, 2024, may result in delisting, although the company can appeal to a Nasdaq Hearings Panel.
December 05, 2023 | 2:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kintara Therapeutics has been granted a deadline extension by Nasdaq to meet stockholders' equity requirements, with a new deadline of March 18, 2024, to avoid delisting.
The extension provides Kintara with additional time to meet Nasdaq's listing requirements, which may be viewed positively by investors as it temporarily alleviates the immediate risk of delisting. However, the underlying issue of meeting the compliance requirements remains, and failure to do so by the new deadline could lead to negative consequences for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100